Establishment of the Interdepartmental Substance Use Disorders Coordinating Committee and Solicitation of Nominations for Committee Members, 21792-21794 [2019-09969]
Download as PDF
<![CDATA[
jbell on DSK3GLQ082PROD with NOTICES
21792
Federal Register / Vol. 84, No. 94 / Wednesday, May 15, 2019 / Notices
In carrying out its mission, the
Advisory Council will provide advice,
information, and recommendations to
the Secretary regarding programs and
policies intended to preserve the
effectiveness of antibiotics by
optimizing their use; advance research
to develop improved methods for
combating antibiotic resistance and
conducting antibiotic stewardship;
strengthen surveillance of antibioticresistant bacterial infections; prevent
the transmission of antibiotic-resistant
bacterial infections; advance the
development of rapid point-of-care and
agricultural diagnostics; further research
on new treatments for bacterial
infections; develop alternatives to
antibiotics for agricultural purposes;
maximize the dissemination of up-todate information on the appropriate and
proper use of antibiotics to the general
public and human and animal
healthcare providers; and improve
international coordination of efforts to
combat antibiotic resistance.
The public meeting will be dedicated
to the council’s deliberation and vote on
the National Action Plan (NAP) on
Combating Antibiotic Resistance
Bacteria (CARB) 2019 Working Group’s
(WG) report out on their draft response
to the Secretary of the Department of
Health and Human Services (HHS) on
identifying priority areas for the next
iteration of the NAP on CARB, 2020–
2025. The remainder of the two-day
public meeting will include panel
presentations and council discussions
surrounding emerging antifungals, and
provider challenges and educational
solutions to influence antibiotic
stewardship and One Health. The
meeting agenda will be posted on the
Advisory Council website at https://
www.hhs.gov/ash/carb/ when it has
been finalized. All agenda items are
tentative and subject to change.
Public attendance at the meeting is
limited to the available space.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Advisory Council at the
address/telephone number listed above
at least one week prior to the meeting.
For those unable to attend in person, a
live webcast will be available. More
information on registration and
accessing the webcast can be found at
https://www.hhs.gov/ash/carb/.
Members of the public will have the
opportunity to provide comments prior
to the Advisory Council meeting by
emailing CARB@hhs.gov. Public
comments should be sent in by
midnight July 2, 2019, and should be
limited to no more than one page. All
VerDate Sep<11>2014
22:43 May 14, 2019
Jkt 247001
public comments received prior to July
2, 2019, will be provided to Advisory
Council members; comments are limited
to five minutes per speaker.
Dated: May 2, 2019.
Jomana F. Musmar,
Designated Federal Officer, Presidential
Advisory Council on Combating AntibioticResistant Bacteria, Committee Manager.
[FR Doc. 2019–09971 Filed 5–14–19; 8:45 am]
BILLING CODE 4150–44–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Establishment of the Interdepartmental
Substance Use Disorders Coordinating
Committee and Solicitation of
Nominations for Committee Members
Office of the Assistant
Secretary for Health, Office of the
Secretary, U.S. Department of Health
and Human Services.
ACTION: Notice.
AGENCY:
The U.S. Department of
Health and Human Services (HHS)
hereby announces the establishment of
the Interdepartmental Substance Use
Disorders Coordinating Committee
(Committee) pursuant to Section 7022 of
the Substance Use-Disorder Prevention
that Promotes Opioid Recovery and
Treatment for Patients and Communities
Act. The Committee will consist of
representatives of specific federal
agencies and non-federal individuals
and entities who represent diverse
disciplines and views. The Committee
will identify areas for improved
coordination related to substance abuse,
including research, services, supports
and prevention activities across all
relevant Federal agencies. In identifying
areas for coordination, the committee
will provide recommendations for
improving Federal programs for the
prevention and treatment of, and
recovery from, substance use disorders,
including by expanding access to
prevention, treatment and recovery
services. They will also analyze
substance use disorder prevention and
treatment strategies in different regions
of and populations in the United States
and evaluate the extent to which
Federal substance use disorder and
treatment strategies are aligned with
State and local substance disorder and
treatment strategies.
Through this notice, HHS is also
requesting nominations of individuals
who are interested in being considered
for appointment to the Committee.
Resumes or curricula vitae from
qualified individuals who wish to be
considered for appointment as a
SUMMARY:
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
member of the Committee are currently
being accepted.
DATES: Nominations must be received
no later than 11:59 p.m. June 14, 2019.
ADDRESSES: All nominations must be
submitted via email at SUDCommittee@
hhs.gov with the subject line:
Interdepartmental SUD Coordinating
Committee.
FOR FURTHER INFORMATION CONTACT:
Roula K. Sweis, Psy.D., M.A., Chief,
Operations and Management, Office of
the Assistant Secretary for Health; U.S.
Department of Health and Human
Services; Telephone: 202–260–6619;
Fax: 202–690–4631; Email address:
SUDCommittee@hhs.gov (please
indicate in the subject line:
Interdepartmental SUD Coordinating
Committee). The Committee charter may
be accessed online at https://
www.hhs.gov/ash/advisory-committees/
substance-use-disorders/.
The charter includes detailed
information about the purpose,
function, and structure of the
Committee.
Section
7022 of the Substance Use-Disorder
Prevention that Promotes Opioid
Recovery and Treatment for Patients
and Communities Act (SUPPORT Act,
Pub. L. 115–271) requires the HHS
Secretary, in coordination with the
Director of National Drug Control
Policy, to establish the
Interdepartmental Substance Use
Disorders Coordinating Committee. The
Committee will consist of
representatives of specific federal
agencies and non-federal individuals
and entities who represent diverse
disciplines and views. The Committee
will identify areas for improved
coordination related to substance abuse,
including research, services, supports
and prevention activities across all
relevant Federal agencies. In identifying
areas for coordination, the committee
will provide recommendations for
improving Federal programs for the
prevention and treatment of, and
recovery from, substance use disorders,
including by expanding access to
prevention, treatment and recovery
services. They will also analyze
substance use disorder prevention and
treatment strategies in different regions
of and populations in the United States
and evaluate the extent to which
Federal substance use disorder and
treatment strategies are aligned with
State and local substance disorder and
treatment strategies.
Objectives and Scope of Activities.
The Committee will perform the
following duties:
SUPPLEMENTARY INFORMATION:
E:\FR\FM\15MYN1.SGM
15MYN1
jbell on DSK3GLQ082PROD with NOTICES
Federal Register / Vol. 84, No. 94 / Wednesday, May 15, 2019 / Notices
(1) Identify areas for improved
coordination of activities, if any, related
to substance use disorders, including
research, services, supports, and
prevention activities across all relevant
Federal agencies;
(2) identify and provide to the
Secretary recommendations for
improving Federal programs for the
prevention and treatment of, and
recovery from, substance use disorders,
including by expanding access to
prevention, treatment, and recovery
services;
(3) analyze substance use disorder
prevention and treatment strategies in
different regions of and populations in
the United States and evaluate the
extent to which Federal substance use
disorder prevention and treatment
strategies are aligned with State and
local substance use disorder prevention
and treatment strategies;
(4) make recommendations to the
Secretary regarding any appropriate
changes with respect to the activities
and strategies described in paragraphs
(1) through (3);
(5) make recommendations to the
Secretary regarding public participation
in decisions relating to substance use
disorders and the process by which
public feedback can be better integrated
into such decisions; and
(6) make recommendations to ensure
that substance use disorder research,
services, supports, and prevention
activities of the Department of Health
and Human Services and other Federal
agencies are not unnecessarily
duplicative.
Membership and Designation. The
Committee shall be composed of the
following Federal (ex-officio) members:
The Secretary of HHS or designee, who
shall serve as the Chair of the
Committee; the Attorney General of the
United States or designee; the Secretary
of Labor or designee; the Secretary of
Housing and Urban Development or
designee; the Secretary of Education or
designee; the Secretary of Veterans
Affairs or designee; the Commissioner of
Social Security or designee; the
Assistant Secretary for Mental Health
and Substance Use or designee; and the
Director of National Drug Control Policy
or designee. Representatives of other
Federal agencies that support or
conduct activities or programs related to
substance abuse disorders, as
determined appropriate by the
Secretary.
The Committee shall include a
minimum of 15 non-Federal members
appointed by the Secretary as special
government employees (SGEs). These
members will be appointed to terms of
three years and may be reappointed for
VerDate Sep<11>2014
22:43 May 14, 2019
Jkt 247001
one or more additional three-year terms.
A vacancy on the Committee will be
filled in the same manner in which the
original appointment was made. Any
individual appointed to fill a vacancy
for an unexpired term will be appointed
for the remainder of such a term and
may serve after the expiration of such
term until a successor has been
appointed. No member of the
Committee shall serve as a
Representative member.
At least two members shall be
individuals who have received
treatment for a diagnosis of substance
use disorder; at least two members shall
be directors of State substance abuse
agencies; at least two members shall be
representatives of leading research,
advocacy or service organizations for
individuals with substance use
disorders; at least two members shall be
a physician, licensed mental health
professional, advance practice registered
nurse, or physician assistant; and have
experience in treating individuals with
substance use disorders; at least one
member shall be a substance use
disorder treatment professional who
provides treatment services at a certified
opioid treatment program; at least one
member shall be a substance use
disorder treatment professional who has
research or clinical experience in
working with racial and ethnic minority
populations; at least one member shall
be a substance use disorder treatment
professional who has research or
clinical mental health experience in
working with medically underserved
populations; at least one member shall
be a State certified substance use
disorder peer support specialist; at least
one member shall be a drug court judge
or judge with experience in adjudicating
cases related to substance use disorders;
and at least one member shall be an
individual with experience providing
services for homeless individuals with a
substance use disorder.
Pursuant to advance written
agreement, each non-federal member of
the Committee will waive his or her
right to compensation for performing
services as a member of the Committee.
However, non-federal members shall
receive per diem and reimbursement for
travel expenses incurred in relation to
performing duties for the Commission,
as authorized by the Federal Advisory
Committee Act (FACA) and 5 U.S.C.
5703 for persons who are employed
intermittently to perform services for
the Federal government and in
accordance with Federal travel
regulations. Ex-officio members of the
Commission remain covered under their
current compensation system.
PO 00000
Frm 00046
Fmt 4703
Sfmt 4703
21793
Estimated Number and Frequency of
Meetings. The Committee will meet not
less than two times a year each year,
and these may be conducted by
teleconference or video conference at
the discretion of the DFO. The meetings
will be open to the public, except as
determined otherwise by the Secretary,
or other official to whom authority has
been delegated, in accordance with the
guidelines under Government in the
Sunshine Act, 5 U.S.C. 552b(c). Notice
of all meetings will be provided to the
public in accordance with the FACA.
Meetings will be conducted and records
of the proceedings will be kept, as
required by applicable laws and
departmental policies. A quorum for the
conduct of business by the full
Committee will consist of a majority of
current appointed members.
When the Secretary or Secretary’s
designee determines that a meeting will
be closed or partially closed to the
public, in accordance with stipulations
of Government in the Sunshine Act, 5
U.S.C. 552b(c), then a report will be
prepared by the DFO that includes, at a
minimum, a list of members and their
business addresses, the Committee’s
functions, date and place of the meeting,
and a summary of the Committee’s
activities and recommendations made
during the fiscal year. A copy of the
report will be provided to the
Department Committee Management
Officer.
Nominations. Nominations, including
self-nominations, of individuals who
have the specified expertise and
knowledge will be considered for
appointment as members of the
Committee. A nomination should
include, at a minimum, the following
for each nominee: (1) A letter of
nomination that clearly states the name
and affiliation of the nominee, the basis
for the nomination, and a statement
from the nominee that indicates that the
individual would be willing to serve as
a member of the Committee (if being
nominated by someone else); (2) the
address, telephone number, and email
address of the individual being
nominated and the nominator (if
applicable); and (3) a current copy of the
nominee’s curriculum vitae or resume,
which should be limited to no more
than 10 pages. Incomplete nomination
packages will not be reviewed.
Every effort will be made to ensure
that the composition of the Committee
includes individuals from various
geographic locations, including rural
and underserved areas; racial and ethnic
minorities; genders, and persons living
with disabilities. Individuals other than
officers or employees of the United
States government being considered for
E:\FR\FM\15MYN1.SGM
15MYN1
21794
Federal Register / Vol. 84, No. 94 / Wednesday, May 15, 2019 / Notices
appointment as members of the
Committee will be required to complete
and submit a report of their financial
holdings. An ethics review must be
conducted to ensure that individuals
appointed as members of the Committee
are not involved in any activity that may
pose a potential conflict of interest for
the official duties that are to be
performed. This is a federal ethics
requirement that must be satisfied upon
entering the position and annually
throughout the established term of
appointment on the Committee.
Authority: The Interdepartmental
Substance Use Disorders Coordinating
Committee (hereafter referred to as the
Committee) is required under Section
7022 of the Substance Use-Disorder
Prevention that Promotes Opioid
Recovery and Treatment for Patients
and Communities Act (SUPPORT Act,
Pub. L. 115–271). The Committee is
governed by the provisions of the
Federal Advisory Committee Act, Public
Law 92–463, as amended (5 U.S.C.
App), which sets forth standards for the
formation and use of federal advisory
committees.
Dated: May 6, 2019.
Roula K. Sweis,
Designated Federal Official.
[FR Doc. 2019–09969 Filed 5–14–19; 8:45 am]
BILLING CODE 4150–28–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
jbell on DSK3GLQ082PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel;
Psychosocial Risk and Disease Prevention
(PRDP).
Date: June 10, 2019.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
VerDate Sep<11>2014
22:43 May 14, 2019
Jkt 247001
Place: Embassy Suites at the Chevy Chase
Pavilion, 4300 Military Road NW,
Washington, DC 20015.
Contact Person: Weijia Ni, Ph.D., Chief/
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3100,
MSC 7808, Bethesda, MD 20892, (301) 594–
3292, niw@csr.nih.gov.
Name of Committee: Cell Biology
Integrated Review Group, Molecular and
Integrative Signal Transduction Study
Section.
Date: June 11–12, 2019.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Charles Selden, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive Room 5187
MSC 7840, Bethesda, MD 20892, 301–451–
3388, seldens@mail.nih.gov.
Name of Committee: Healthcare Delivery
and Methodologies Integrated Review Group;
Dissemination and Implementation Research
in Health Study Section.
Date: June 12–13, 2019.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Renaissance New Orleans Pere
Marquette, 817 Common Street, New
Orleans, LA 1855201.
Contact Person: Yvonne Owens Ferguson,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive Room 3139,
Bethesda, MD 20892, 301–827–3689,
fergusonyo@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel;
Fellowships: Biophysical, Physiological,
Pharmacological and Bioengineering
Neuroscience.
Date: June 13–14, 2019.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Residence Inn Bethesda, 7335
Wisconsin Avenue, Bethesda, MD 20814.
Contact Person: Sussan Paydar, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, RM 5222,
Bethesda, MD 20817, (301) 827–4994,
sussan.paydar@nih.gov.
Name of Committee: Oncology 1-Basic
Translational Integrated Review Group;
Cancer Genetics Study Section.
Date: June 13–14, 2019.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hilton Washington/Rockville, 1750
Rockville Pike, Rockville, MD 20852.
Contact Person: Juraj Bies, Ph.D., Scientific
Review Officer, Center for Scientific Review,
National Institutes of Health, 6701 Rockledge
Drive, Room 4158, MSC 7806, Bethesda, MD
20892, 301 435 1256, biesj@mail.nih.gov.
Name of Committee: Brain Disorders and
Clinical Neuroscience Integrated Review
PO 00000
Frm 00047
Fmt 4703
Sfmt 4703
Group; Clinical Neuroimmunology and Brain
Tumors Study Section.
Date: June 13–14, 2019
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Renaissance, Washington, DC Hotel,
999 Ninth Street NW, Washington, DC
20001–4427.
Contact Person: Wei-Qin Zhao, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5181,
MSC 7846, Bethesda, MD 20892–7846, 301–
435–1236, zhaow@csr.nih.gov.
Name of Committee: Immunology
Integrated Review Group; Vaccines Against
Microbial Diseases Study Section.
Date: June 13–14, 2019.
Time: 8:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hilton Garden Inn Washington DC
Franklin Square, 815 14th Street NW,
Washington, DC 20005.
Contact Person: Jian Wang, MD, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4218,
MSC 7812, Bethesda, MD 20892, (301) 435–
2778, wangjia@csr.nih.gov.
Name of Committee: Cell Biology
Integrated Review Group, Intercellular
Interactions Study Section.
Date: June 13–14, 2019.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Virtual Meeting).
Contact Person: Thomas Y Cho, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, 6701 Rockledge Drive,
Bethesda, MD 20892, 301–402–4179,
thomas.cho@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Clinical
Neuroscience and Neurodegeneration.
Date: June 13, 2019.
Time: 12:00 p.m. to 1:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Doubletree Hotel Bethesda,
(Formerly Holiday Inn Select), 8120
Wisconsin Avenue, Bethesda, MD 20814.
Contact Person: Samuel C Edwards, Ph.D.,
Chief, BDCN IRG, Center for Scientific
Review, National Institutes of Health, 6701
Rockledge Drive, Room 5210, MSC 7846,
Bethesda, MD 20892, (301) 435–1246,
edwardss@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR Panel:
Cellular and Molecular Biology of Complex
Brain Disorders.
Date: June 14, 2019.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Villa Florence Hotel, 225 Powell
Street, San Francisco, CA 94102.
Contact Person: Afia Sultana, Ph.D.,
Scientific Review Officer, National Institutes
of Health, Center for Scientific Review, 6701
E:\FR\FM\15MYN1.SGM
15MYN1
]]>Agencies
[Federal Register Volume 84, Number 94 (Wednesday, May 15, 2019)]
[Notices]
[Pages 21792-21794]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-09969]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Establishment of the Interdepartmental Substance Use Disorders
Coordinating Committee and Solicitation of Nominations for Committee
Members
AGENCY: Office of the Assistant Secretary for Health, Office of the
Secretary, U.S. Department of Health and Human Services.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The U.S. Department of Health and Human Services (HHS) hereby
announces the establishment of the Interdepartmental Substance Use
Disorders Coordinating Committee (Committee) pursuant to Section 7022
of the Substance Use-Disorder Prevention that Promotes Opioid Recovery
and Treatment for Patients and Communities Act. The Committee will
consist of representatives of specific federal agencies and non-federal
individuals and entities who represent diverse disciplines and views.
The Committee will identify areas for improved coordination related to
substance abuse, including research, services, supports and prevention
activities across all relevant Federal agencies. In identifying areas
for coordination, the committee will provide recommendations for
improving Federal programs for the prevention and treatment of, and
recovery from, substance use disorders, including by expanding access
to prevention, treatment and recovery services. They will also analyze
substance use disorder prevention and treatment strategies in different
regions of and populations in the United States and evaluate the extent
to which Federal substance use disorder and treatment strategies are
aligned with State and local substance disorder and treatment
strategies.
Through this notice, HHS is also requesting nominations of
individuals who are interested in being considered for appointment to
the Committee. Resumes or curricula vitae from qualified individuals
who wish to be considered for appointment as a member of the Committee
are currently being accepted.
DATES: Nominations must be received no later than 11:59 p.m. June 14,
2019.
ADDRESSES: All nominations must be submitted via email at
[email protected] with the subject line: Interdepartmental SUD
Coordinating Committee.
FOR FURTHER INFORMATION CONTACT: Roula K. Sweis, Psy.D., M.A., Chief,
Operations and Management, Office of the Assistant Secretary for
Health; U.S. Department of Health and Human Services; Telephone: 202-
260-6619; Fax: 202-690-4631; Email address: [email protected]
(please indicate in the subject line: Interdepartmental SUD
Coordinating Committee). The Committee charter may be accessed online
at https://www.hhs.gov/ash/advisory-committees/substance-use-disorders/. The charter includes detailed information about the
purpose, function, and structure of the Committee.
SUPPLEMENTARY INFORMATION: Section 7022 of the Substance Use-Disorder
Prevention that Promotes Opioid Recovery and Treatment for Patients and
Communities Act (SUPPORT Act, Pub. L. 115-271) requires the HHS
Secretary, in coordination with the Director of National Drug Control
Policy, to establish the Interdepartmental Substance Use Disorders
Coordinating Committee. The Committee will consist of representatives
of specific federal agencies and non-federal individuals and entities
who represent diverse disciplines and views. The Committee will
identify areas for improved coordination related to substance abuse,
including research, services, supports and prevention activities across
all relevant Federal agencies. In identifying areas for coordination,
the committee will provide recommendations for improving Federal
programs for the prevention and treatment of, and recovery from,
substance use disorders, including by expanding access to prevention,
treatment and recovery services. They will also analyze substance use
disorder prevention and treatment strategies in different regions of
and populations in the United States and evaluate the extent to which
Federal substance use disorder and treatment strategies are aligned
with State and local substance disorder and treatment strategies.
Objectives and Scope of Activities. The Committee will perform the
following duties:
[[Page 21793]]
(1) Identify areas for improved coordination of activities, if any,
related to substance use disorders, including research, services,
supports, and prevention activities across all relevant Federal
agencies;
(2) identify and provide to the Secretary recommendations for
improving Federal programs for the prevention and treatment of, and
recovery from, substance use disorders, including by expanding access
to prevention, treatment, and recovery services;
(3) analyze substance use disorder prevention and treatment
strategies in different regions of and populations in the United States
and evaluate the extent to which Federal substance use disorder
prevention and treatment strategies are aligned with State and local
substance use disorder prevention and treatment strategies;
(4) make recommendations to the Secretary regarding any appropriate
changes with respect to the activities and strategies described in
paragraphs (1) through (3);
(5) make recommendations to the Secretary regarding public
participation in decisions relating to substance use disorders and the
process by which public feedback can be better integrated into such
decisions; and
(6) make recommendations to ensure that substance use disorder
research, services, supports, and prevention activities of the
Department of Health and Human Services and other Federal agencies are
not unnecessarily duplicative.
Membership and Designation. The Committee shall be composed of the
following Federal (ex-officio) members: The Secretary of HHS or
designee, who shall serve as the Chair of the Committee; the Attorney
General of the United States or designee; the Secretary of Labor or
designee; the Secretary of Housing and Urban Development or designee;
the Secretary of Education or designee; the Secretary of Veterans
Affairs or designee; the Commissioner of Social Security or designee;
the Assistant Secretary for Mental Health and Substance Use or
designee; and the Director of National Drug Control Policy or designee.
Representatives of other Federal agencies that support or conduct
activities or programs related to substance abuse disorders, as
determined appropriate by the Secretary.
The Committee shall include a minimum of 15 non-Federal members
appointed by the Secretary as special government employees (SGEs).
These members will be appointed to terms of three years and may be
reappointed for one or more additional three-year terms. A vacancy on
the Committee will be filled in the same manner in which the original
appointment was made. Any individual appointed to fill a vacancy for an
unexpired term will be appointed for the remainder of such a term and
may serve after the expiration of such term until a successor has been
appointed. No member of the Committee shall serve as a Representative
member.
At least two members shall be individuals who have received
treatment for a diagnosis of substance use disorder; at least two
members shall be directors of State substance abuse agencies; at least
two members shall be representatives of leading research, advocacy or
service organizations for individuals with substance use disorders; at
least two members shall be a physician, licensed mental health
professional, advance practice registered nurse, or physician
assistant; and have experience in treating individuals with substance
use disorders; at least one member shall be a substance use disorder
treatment professional who provides treatment services at a certified
opioid treatment program; at least one member shall be a substance use
disorder treatment professional who has research or clinical experience
in working with racial and ethnic minority populations; at least one
member shall be a substance use disorder treatment professional who has
research or clinical mental health experience in working with medically
underserved populations; at least one member shall be a State certified
substance use disorder peer support specialist; at least one member
shall be a drug court judge or judge with experience in adjudicating
cases related to substance use disorders; and at least one member shall
be an individual with experience providing services for homeless
individuals with a substance use disorder.
Pursuant to advance written agreement, each non-federal member of
the Committee will waive his or her right to compensation for
performing services as a member of the Committee. However, non-federal
members shall receive per diem and reimbursement for travel expenses
incurred in relation to performing duties for the Commission, as
authorized by the Federal Advisory Committee Act (FACA) and 5 U.S.C.
5703 for persons who are employed intermittently to perform services
for the Federal government and in accordance with Federal travel
regulations. Ex-officio members of the Commission remain covered under
their current compensation system.
Estimated Number and Frequency of Meetings. The Committee will meet
not less than two times a year each year, and these may be conducted by
teleconference or video conference at the discretion of the DFO. The
meetings will be open to the public, except as determined otherwise by
the Secretary, or other official to whom authority has been delegated,
in accordance with the guidelines under Government in the Sunshine Act,
5 U.S.C. 552b(c). Notice of all meetings will be provided to the public
in accordance with the FACA. Meetings will be conducted and records of
the proceedings will be kept, as required by applicable laws and
departmental policies. A quorum for the conduct of business by the full
Committee will consist of a majority of current appointed members.
When the Secretary or Secretary's designee determines that a
meeting will be closed or partially closed to the public, in accordance
with stipulations of Government in the Sunshine Act, 5 U.S.C. 552b(c),
then a report will be prepared by the DFO that includes, at a minimum,
a list of members and their business addresses, the Committee's
functions, date and place of the meeting, and a summary of the
Committee's activities and recommendations made during the fiscal year.
A copy of the report will be provided to the Department Committee
Management Officer.
Nominations. Nominations, including self-nominations, of
individuals who have the specified expertise and knowledge will be
considered for appointment as members of the Committee. A nomination
should include, at a minimum, the following for each nominee: (1) A
letter of nomination that clearly states the name and affiliation of
the nominee, the basis for the nomination, and a statement from the
nominee that indicates that the individual would be willing to serve as
a member of the Committee (if being nominated by someone else); (2) the
address, telephone number, and email address of the individual being
nominated and the nominator (if applicable); and (3) a current copy of
the nominee's curriculum vitae or resume, which should be limited to no
more than 10 pages. Incomplete nomination packages will not be
reviewed.
Every effort will be made to ensure that the composition of the
Committee includes individuals from various geographic locations,
including rural and underserved areas; racial and ethnic minorities;
genders, and persons living with disabilities. Individuals other than
officers or employees of the United States government being considered
for
[[Page 21794]]
appointment as members of the Committee will be required to complete
and submit a report of their financial holdings. An ethics review must
be conducted to ensure that individuals appointed as members of the
Committee are not involved in any activity that may pose a potential
conflict of interest for the official duties that are to be performed.
This is a federal ethics requirement that must be satisfied upon
entering the position and annually throughout the established term of
appointment on the Committee.
Authority: The Interdepartmental Substance Use Disorders
Coordinating Committee (hereafter referred to as the Committee) is
required under Section 7022 of the Substance Use-Disorder Prevention
that Promotes Opioid Recovery and Treatment for Patients and
Communities Act (SUPPORT Act, Pub. L. 115-271). The Committee is
governed by the provisions of the Federal Advisory Committee Act,
Public Law 92-463, as amended (5 U.S.C. App), which sets forth
standards for the formation and use of federal advisory committees.
Dated: May 6, 2019.
Roula K. Sweis,
Designated Federal Official.
[FR Doc. 2019-09969 Filed 5-14-19; 8:45 am]
BILLING CODE 4150-28-P
